ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
July 17, 2024 07:25 ET
|
ASLAN PHARMACEUTICALS LIMITED
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
July 17, 2024 07:15 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024 07:07 ET
|
SciSparc Ltd
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
July 17, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Fortrea Announces Date for Second Quarter 2024 Financial Results and Conference Call
July 17, 2024 07:00 ET
|
Fortrea Holdings Inc
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter...
Universal Stainless to Webcast Second Quarter 2024 Results Conference Call on July 31st
July 17, 2024 07:00 ET
|
Universal Stainless & Alloy Products, Inc.
BRIDGEVILLE, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- Universal Stainless & Alloy Products, Inc. (Nasdaq: USAP) announced today that it will report financial results for the second quarter of 2024...
Bitfarms’ Newly Appointed CEO to Participate Today in a Fireside Chat Hosted by H.C. Wainwright
July 17, 2024 07:00 ET
|
Bitfarms Ltd.
TORONTO, Ontario and BROSSARD, Québec, July 17, 2024 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin data center company, announces its...
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
July 17, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
July 17, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary...